| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 29.3 | 22.6 |
| Gross profit | 26.3 | 19.9 |
| Profit before tax | -21.4 | -13.5 |
| Net income | -21.4 | -13.5 |
| EPS (diluted, $ a share) | $-0.55 | $-0.37 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +29.9% |
|---|---|
| Gross margin | 89.8% |
| Operating margin | -70.0% |
10-Q filed with the SEC, NASDAQ: CBLL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ceribell, Inc.: key numbers
- Share price
- $25.97Close, Nov 17
- Market cap
- $1.01B
- Shares outstanding
- 38.84MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Electromedical & Electrotherapeutic ApparatusSIC 3845
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ceribell, Inc.
All →Ceribell Director William W. Burke Sells $479K of Stock
William W. Burke, Director, sold 18,000 shares of Ceribell, Inc. at $26.58 to $27.48 a share (average $26.64) in 2 transactions, worth $479K in total on Nov 12, 2026. Shares held after the trade: 23,022 (-4.8%).
- Value
- $479K
- Shares
- 18,000
- Average price
- $26.64
- Role
- Director
- Holding change
- -4.8%
- Trade date
- Nov 12, 2026
Ceribell Director Joseph Michael Taylor Sells $278K of Stock
Joseph Michael Taylor, Director, sold 10,200 shares of Ceribell, Inc. at $27.22 a share, worth $278K in total on Nov 9, 2026. Shares held after the trade: 38,278 (-21.0%).
- Value
- $278K
- Shares
- 10,200
- Price
- $27.22
- Role
- Director
- Holding change
- -21.0%
- Trade date
- Nov 9, 2026
Ceribell CTO Raymond Woo Sells $132K of Stock
Raymond Woo, CTO, sold 4,887 shares of Ceribell, Inc. at $26.96 a share, worth $132K in total on Nov 2, 2026. Shares held after the trade: 203,118 (-2.3%).
- Value
- $132K
- Shares
- 4,887
- Price
- $26.96
- Role
- CTO
- Holding change
- -2.3%
- Trade date
- Nov 2, 2026
Ceribell Financial Results
Ceribell reported Q3 2026 total revenue of $29.3 million, a 30% year-over-year increase driven by record account additions and same-store utilization growth. The company achieved a 90% gross margin and ended the period with $117.5 million in cash and marketable securities. Key operational milestones included the full launch of its delirium monitoring solution and receiving FDA 510(k) clearance for new EEG analysis features.
- Term
- Q3 2026
“Our third quarter results reflect new highs in account additions and utilization within our existing account base, demonstrating the strength of our core seizure business as a durable growth engine. With the full launch of our delirium monitoring solution and the coming introduction of our new hardware platform, we are well positioned for a pivotal 2027 as we advance our mission to establish EEG as a new vital sign.”
Jane Chao, Ph.D., co-founder and CEO
Ceribell CTO Raymond Woo Sells $119K of Stock
Raymond Woo, CTO, sold 4,887 shares of Ceribell, Inc. at $24.38 a share, worth $119K in total on Oct 1, 2026. Shares held after the trade: 203,118 (-2.3%).
- Value
- $119K
- Shares
- 4,887
- Price
- $24.38
- Role
- CTO
- Holding change
- -2.3%
- Trade date
- Oct 1, 2026